Because M-COPA had a potent antitumor effect on NSCLC cells with acquired resistance to first-generation EGFR-TKIs, we next investigated the antitumor activity of M-COPA on NSCLC cells that had acquired resistance to a third-generation EGFR-TKIs. This evidence concerns the gene EGFR and non-small cell lung carcinoma.